Calcium channel blockers depress atrioventricular (AV) nodal properties in vivo in a frequencydependent manner, suggesting that selective drug action during supraventricular arrhythmias may result from use-dependent properties. The present study was designed to examine whether or not the rate-dependent actions of diltiazem account for its therapeutic effects during atrial fibrillation. The determinants of the ventricular response to atrial fibrillation (concealed AV nodal conduction and AV node functional refractory period, AVFRP) were evaluated at multiple cycle lengths (with extrastimulus techniques) and during electrically induced atrial fibrillation (with indirect indexes from RR interval histograms) in anesthetized dogs. In the presence of diltiazem, AVFRP increased progressively relative to control as rate accelerated. At cycle lengths comparable to sinus rhythm in humans, AVFRP increased 10%, 17%, and 32% after doses 1, 2, and 3 of diltiazem, respectively. Drug-induced increases in AVFRP were greater at basic cycle lengths just above the Wenckebach point (17%, 48%, and 81%) and were maximal during atrial fibrillation (39%, 86%, and 154% increases for doses 1, 2, and 3, respectively). Diltiazem also increased the AV conduction system effective refractory period in a frequency-dependent manner without affecting the atrial effective refractory period, thereby increasing the potential zone of concealment into the AV node. Frequency-dependent increases in the zone of concealment were produced by diltiazem and were associated with marked increases in the standard deviation of RR interval histograms during atrial fibrillation (257%, 526%, and 923% increases after doses 1, 2, and 3, respectively). The combination of rate-dependent increases in AVFRP and zone of concealment resulted in a marked amplification of diltiazem's effects during atrial fibrillation, with mean RR interval increases (88%, 200%, and 300% after doses 1, 2, and 3, respectively) that were 8-10 fold greater than increases in AVFRP at cycle lengths comparable to sinus rhythm in humans. We conclude that diltiazem's frequency-dependent effects lead to highly selective depression of AV nodal function during atrial fibrillation. (Circulation 1989;80:380- 
diastolic intervals. [4] [5] [6] [7] [8] We have recently shown that verapamil, diltiazem, and nifedipine slow atrioventricular (AV) nodal conduction and prolong AV nodal refractoriness in vivo in a frequencydependent manner and that the time course of recovery of AV conduction slowing is specific to the drug studied.9 On the basis of these observations, we hypothesized that these agents would have more profound effects on AV nodal properties during supraventricular tachyarrhythmias than during sinus rhythm. This would lead to desirable selectivity in their action during the very arrhythmias for which they are used. However, this hypothesis has not been directly tested in either spontaneous or experimentally induced arrhythmias.
Atrial fibrillation is an example of a supraventricular arrhythmia for which use-dependent drug effects may be particularly important in determining efficacy, because atrial impulses at rates of 400-600/min result in a high input rate to the AV node.10 Verapamil and diltiazem have been effective in controlling the ventricular rate during this arrhythmia.1'-15 The determinants of the ventricular response during atrial fibrillation include the functional refractory period of the AV node (AVFRP) and concealed AV nodal conduction resulting from intranodal impulse block. [16] [17] [18] [19] [20] Preferential salutary effects of calcium channel blockers during atrial fibrillation could be produced by rate-dependent changes in either AVFRP or the degree of concealed conduction in the AV node.
The purpose of this study was to examine the effects of diltiazem on the ventricular response during experimental atrial fibrillation and to relate these effects to rate-related changes in functional refractoriness and concealed AV nodal conduction to determine the clinical relevance of frequencydependent drug actions.
Methods

General
Mongrel dogs of either sex were anesthetized with morphine (2 mg/kg s.c.) and a-chloralose (100 mg/kg i.v.). Catheters were inserted into both femoral veins and arteries and were kept patent with heparinized saline (0.9%). Dogs were ventilated through an endotracheal tube with a Harvard animal respirator (South Natick, Massachusetts). Tidal volume and respiratory rate were adjusted after measurement of arterial blood gases to ensure adequate oxygenation (Sao2 .90%) and physiologic pH (7.35 to 7.45) . A thoracotomy was performed through the fourth right intercostal space. After suspension of the heart in a pericardial cradle, two bipolar Teflon-coated stainless steel electrodes were inserted into the right atrial appendage for recording and stimulation. Body temperature was monitored continuously with a thermistor within the chest cavity and was maintained at 37-38°C by a homeothermic heating blanket. A Statham P23 ID transducer (Cleveland, Ohio), electrophysiologic amplifiers, and a paper recorder (Siemens Mingograf 80, Sweden ) were used to record blood pressure, electrocardiographic leads II and aVR, a right atrial electrogram, and stimulus artifacts. Stimulation was applied with 4-msec square-wave impulses at twice late diastolic threshold. The sinus node was crushed to allow for a wide range of pacing rates.
All dogs were autonomically blocked to measure direct drug effects without contamination by autonomic reflex changes. Vagal effects were prevented by surgical division of the cervical vagi followed by intravenous administration of 1 mg atropine. ,BBlockade was produced by administration of 0.5 mg/kg atenolol. Repeated doses of atropine (0.5 mg) and atenolol (0.25 mg/kg) were administered hourly. This regimen has previously produced sustained autonomic blockade.9,21
Experimental Protocol
Experiments were conducted to assess 1) the frequency-dependent effects of diltiazem on AV nodal refractoriness during atrial pacing and induced atrial fibrillation (eight dogs) and 2) the frequencydependent effects of diltiazem on concealed AV nodal conduction (four additional dogs).
Atrioventricular nodal refractoriness (atrial pacing and atrialfibrillation). Wenckebach cycle length was determined under control conditions by decreasing atrial pacing cycle length by 10 msec decrements until second-degree AV block occurred. This was repeated before and after each experimental protocol to ensure stability of AV nodal function during electrophysiologic study under control conditions and during each drug infusion. The functional refractory period of the AV conduction system (AVFRP) was determined by introducing single premature stimuli (S2) after 20 basic (S,) stimuli. The resulting VIV2 interval was measured, and a curve relating V1V2 to the S1S2 interval was established. The AVFRP was defined as the shortest V1V2 resulting from premature atrial stimulation. This process was repeated at multiple basic cycle lengths (S1S1) ranging from 300 to 1,000 msec. The effective refractory period of the AV conduction system (AVERP) was defined as the longest A1A2 failing to result in a propagated ventricular response and was determined at the same cycle lengths. The atrial effective refractory period (AERP) was also determined at a pacing cycle length of 600 msec.
After determination of the AERP, AVERP, and AVFRP, atrial fibrillation was induced by continuous atrial stimulation at 10-50 Hz.17 '22 In each experiment, atrial pacing cycle length was adjusted until the resultant ventricular response was consistently irregular. Pacing-induced atrial fibrillation was confirmed in each case by observing irregular atrial activity in the electrocardiographic and intracardiac recordings and by the persistence of spontaneous atrial fibrillation lasting between several seconds and several minutes after the interruption of pacing. Two minutes after induction of atrial fibrillation, a continuous electrocardiographic recording lasting 5-10 minutes was obtained. Because AV nodal conduction slowing in the presence of diltiazem requires time to reach steady state during pacing at any given rate,9 all determinations of refractoriness during steady-state pacing or atrial fibrillation were preceded by pacing for 2 minutes.
After control measurements were completed, incremental doses of diltiazem were infused intravenously, and the experimental protocol was repeated. The dosing regimens used were developed in previously published experiments9 and were designed to result in steady-state concentrations spanning the range of concentrations observed after therapeutic doses of diltiazem in humans. The elec- Consecutive RR intervals during induced atrial fibrillation were measured, and RR interval histograms were constructed.19 A minimum of 500 ventricular complexes were analyzed during each period of atrial fibrillation. The mean, minimum, and standard deviation of RR intervals were calculated for each histogram. The minimum RR interval during atrial fibrillation was used as an index of the func-tional refractory period of the AV node during atrial fibrillation. 10, 19, 26 Group data are presented as the mean+SD. Multiple comparisons between control and experimental group means were made by two-way analysis of variance with Scheflfs test or by the unpaired t test with Bonferroni's correction.27 Two-tailed tests were used for all statistical comparisons, and a probability of 5% or less was considered as significant.
The range of cycle lengths that could be studied was limited by the Wenckebach cycle length and spontaneous automaticity, which determined the shortest and longest pacing cycle length, respectively, under any experimental condition. Because the range of cycle lengths studied varied between experiments, we analyzed results in terms of the longest and shortest cycle length in each experiment during each drug infusion. Results in the presence of diltiazem were compared with results under control conditions at the same cycle length within each experiment. Effects of a given infusion at the longest cycle in each experiment were then grouped for statistical analysis as were effects at the shortest cycle length.
Plasma diltiazem concentration was measured by reverse-phase high-performance liquid chromatography (HPLC). Plasma samples (0.5 ml) were extracted with 0.1 ml 1N hydrochloric acid, into 2.5 ml dichloromethane to which 15 gl internal standard solution (16 gg/ml L-8040, kindly supplied by Ayerst Laboratories, Montreal, Canada) had been added. After it had been thoroughly mixed, the solution was dried under nitrogen gas and reconstituted with 45 gl mobile phase (95% methanol in water, with 0.3 ml/l glacial acetic acid and 2 g/l octanesulfonic acid). The resulting solution was injected onto a 5-g ODS column (Chromatography Sciences, Montreal, Canada). Diltiazem was detected by a Waters ultraviolet absorbance meter at a wave length of 237 nm. The retention times for diltiazem and internal standard were 6 and 7.5 minutes, respectively, at a flow rate of 2.5 ml/min. Figure 1 . After the infusion of diltiazem, the RR interval histogram recorded during atrial fibrillation was shifted to the right with an increase in the minimum RR interval (index for AVFRP during atrial fibrillation) and the mean ventricular response (mean RR interval) (Figure 2 ). The mean ventricular response was substantially slowed by the drug ( Table 2 ). The shape of the RR interval histogram was also altered by the administration of diltiazem. In all cases, the range of RR intervals increased markedly so that the mean RR interval was prolonged to a greater extent than the minimum RR interval recorded ( Figure 2 ). This "splaying out" of the RR interval histogram corresponded to a concentrationdependent increase in the standard deviation of histograms after drug administration ( Results shown are for four experiments after dose 1, eight experiments after dose 2, and five experiments after dose 3. Matching control data (obtained at identical cycle lengths in the case of AVFRP at S-BCL and L-BCL) are displayed with posttreatment values. Percent change over control are shown in parentheses. Cycle lengths at which AVFRP at S-BCL was obtained averaged 375±50, 463±52, and 540±114 msec, for doses 1, 2, and 3, respectively. Corresponding cycle lengths at which AVFRP at L-BCL was obtained averaged 825±126, 863±160, and 1,000±0 msec. Mean±SD of raw data is expressed in msec.
Mean RR, mean RR interval during electrically induced atrial fibrillation; SD, standard deviation of RR intervals from the mean value during atrial fibrillation; AVFRP, functional refractory period of the atrioventricular conduction system, measured indirectly during atrial fibrillation (AF) as the minimum RR interval (Min RR) observed, during pacing at the shortest basic cycle length obtainable (S-BCL) and during pacing at the longest basic cycle length possible (L-BCL).
*p<0.05, **p<0.01, ***p<0.001 vs. control values. the shortest and longest pacing cycle lengths available and the changes in minimum RR interval during atrial fibrillation. After dose 1 of diltiazem, a mean increase of 10% in AVFRP over control was observed at the longest cycle length studied, whereas a 39% increase in minimum RR interval (index for AVFRP) was noted during experimental atrial fibrillation. Similar rate-dependent increases in AVFRP were observed after doses 2 and 3. Although the longest absolute values of AVFRP after drug administration were noted during pacing at the shortest pacing cycle length, larger percent increases in minimum RR interval during atrial fibrillation were observed at all doses (Table 2, Figure 4) .
The relation between diltiazem's effects on mean ventricular response and AVFRP are displayed in Figure 4 . The increase in mean ventricular response produced by diltiazem during atrial fibrillation was much larger than the drug's effect on AVFRP at long cycle lengths, and the former effect averaged 8.9, 10.9, and 9.4 times larger than the latter effect for doses 1, 2, and 3, respectively. Frequencydependent increases in AVFRP accounted for approximately one half of the 10-fold increase in drug effect observed during atrial fibrillation (3.9-4.8 fold increases in AVFRP). FIGURE 6. Plot of atrioventricular conduction time as a function of atrial coupling interval (S1S2) in the absence and presence of concealed atrial extrastimuli in a typical experiment. Under control conditions with a basic cycle length of 500 msec, AV conduction time was exponentially related to S1S2. After diltiazem administration, in the absence of an interpolated atrial extrastimulus (S1S'=0), the curve was shifted upward and to the right. Interpolation of nonconducted atrial stimuli (S') between the last beat of the basic train (S1) and the test stimulus (S2) resulted in a further shift of the curve to the right (i.e., concealed conduction). Concealed atrial stimuli with a coupling interval 30 msec greater than atrial effective refractoryperiod (S1S' early) displaced the curve to a lesser extent than did concealed atrial extrastimuli at a coupling interval 10 msec shorter than atrioventricular effective refractory pertiod (S1S' late) or atrial extrastimuli with an intermediate coupling interval (S1S' mid).
less than the AVERP. However, the length of the zone during which atrial impulses were concealed depended on underlying heart rate, and larger zones were observed at shorter cycle lengths ( Figure 7 ).
Discussion
Understanding of antiarrhythmic drug action has improved with the appreciation that cardiac frequency is an important modulator of drug action and that important differences in frequencydependent properties exist within a specific class of drugs. These concepts have been incorporated into recent models of antiarrhythmic drug action.28,29 Although frequency-dependent effects on cardiac conduction and refractoriness in vivo have been documented, their importance in determining antiarrhythmic efficacy has not been adequately addressed.
We have previously demonstrated that calcium channel blockers have important frequencydependent effects on AV nodal conduction and refractoriness.9 Because atrial fibrillation results in a very fast input rate into the AV node, rapid AV nodal activation in the presence of calcium channel blockers should result in increased block of inward calcium current and a slower ventricular response rate. This would lead to enhancement of antiarrhythmic drug effects by the very tachyarrhythmias for which these drugs are used and would lead to desirable selectivity of drug action. We found that diltiazem's actions during atrial fibrillation were disproportional to its effects at cycle lengths comparable to resting sinus rhythm. Progressive amplification by increases in atrial rate led to maximal effects during atrial fibrillation. Although several models have been proposed to account for the ventricular response to atrial fibrillation, [16] [17] [18] [19] [20] 22, [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] our results can be understood by the classic mechanisms proposed by Langendorf16 and extended by others. [17] [18] [19] [20] 22, 36 It is assumed that rapid, irregular atrial impulses penetrate the AV node with variable strength from multiple directions. The resulting ventricular response is determined by two factors: 1) the functional refractory period of the AV node,19,26,30 which constrains the maximum exit rate from the AV node, and 2) the role of concealed AV nodal responses. 16, 17, 22 Our results suggest that the beneficial effects of diltiazem during atrial fibrillation are secondary to increases in both the AVFRP and the impairment in AV nodal conduction resulting from concealed AV nodal responses. Moreover, these effects on AV nodal properties were markedly dependent on stimulation rate, implying that frequencydependent drug-receptor interactions may be responsible for maximizing drug effects during tachyarrhythmias.
We found that the percentage by which diltiazem increased AVFRP became progressively larger as atrial rate increased and that the largest percent increases were observed during atrial fibrillation. The rate dependence of AVFRP in the presence of diltiazem was the opposite of that described in the absence of drug41-44 (as confirmed by our control my~1 observations). The AVFRP is not a pure index of AV nodal refractoriness. It is directly related to the coupling interval at which the slope of the AV recovery curve (AH plotted against A1A2) equals unity.43 Thus, increases in the AVERP, which shift the AV recovery curve to longer atrial coupling intervals, lead to increases in the AVFRP. In addition, AVFRP is inversely related to the conduction time of A, and directly related to the conduction time of A2 during extrastimulus testing.43i44 Nonetheless, AVFRP remains a useful measure clinically and conceptually because it equals the minimum coupling interval at which impulses can exit from the AV node, and as such, AVFRP constrains the maximum ventricular rate that can occur during rapid atrial rhythms. In addition, Billette45 showed that the functional refractory period is determined by the action potential duration of cells within the distal portion of the AV node.
We used the minimum RR interval observed during atrial fibrillation as an index of the AVFRP during this arrhythmia. Although the minimum RR interval is not a direct measure of the functional refractory period, it is directly proportional to the AVFRP measured by the extrastimulus technique,19 and it correlates with the mean ventricular response during experimental atrial fibrillation.20 Because the percentage by which diltiazem increased AVFRP rose progressively during accelerations in atrial pacing associated with 1:1 AV conduction, we would expect that at least comparable increases would be observed during atrial fibrillation, when AV nodal activations are more frequent. The increases in minimum RR interval observed during atrial fibrillation are consistent with this interpretation.
Diltiazem-induced increases in the minimum RR interval during atrial fibrillation accounted for approximately one half of the observed slowing of the mean ventricular response during atrial fibrillation. Several observations suggested that raterelated increases in concealed AV nodal conduction were at least as important to diltiazem's beneficial effects. All atrial activations failing to conduct to the ventricles in the presence of the drug caused AV nodal delay of subsequent atrial impulses. Zone of concealment was therefore determined at any cycle length by the difference between the AERP and AVERP. Because diltiazem increased the AVERP in a rate-dependent fashion, without altering atrial refractoriness, it caused a rate-related increase in the difference between AERP and AVERP, and consequently zone of concealment.
The width of the RR interval histograms during atrial fibrillation increased consistently after the administration of diltiazem, implying increases in the quantity of AV node concealment during atrial fibrillation. Similar changes in the RR interval histogram during atrial fibrillation have been observed during oral diltiazem therapy in patients with chronic atrial fibrillation.14 Increases in the amount of concealed conduction, suggested by the observed changes in the RR interval histograms, could be due to a change in the atrial input frequency into the AV node (so that more impulses are likely to fall during zone of concealment), or to an increase in zone of concealment itself. Thiesen and coworkers14 suggested that diltiazem alters the input into the AV node during atrial fibrillation. However, diltiazem did not alter atrial refractoriness in our dogs, and in previous studies, we showed that atrial conduction is also unaffected by diltiazem.9 Because the properties of atrial fibrillation are determined by atrial conduction velocity and refractoriness and because diltiazem affects neither of these variables in autonomically blocked dogs, it is unlikely that the atrial input pattern during atrial fibrillation was altered by diltiazem in our dogs. These considerations, coupled with direct observations of zone of concealment during atrial pacing, are consistent with the hypothesis that the increases in AV nodal concealment produced by diltiazem during atrial fibrillation result from an increase in the concealment zone due to rate-dependent increases in AVERP.
Frequency-dependent increases in AV nodal refractoriness and concealment led to dramatic amplification of diltiazem's effects during atrial fibrillation. The amplification of drug effect by tachycardia is likely related to the preferential binding of diltiazem to AV nodal calcium channels that occurs during depolarization and is followed by drug unbinding after repolarization.29 At slower rates (e.g., in sinus rhythm) diastolic time is longer, allowing more drug unbinding and less AV nodal depression. However, during atrial fibrillation, frequent AV nodal activation limits the recovery time available between impulses, leading to an accumulation of diltiazem binding and enhanced drug effects. This activation increases the AVFRP, increasing the minimum output interval that the AV node can support, and this also increases the AVERP, increasing the number of impulses that block in the AV node and that leave it in a state of increased refractoriness (concealed conduction). Potential Limitations Our model of atrial fibrillation was designed to simulate the chaotic, rapid input into the AV node that occurs during atrial fibrillation in humans. It was not intended to simulate the areas of slowed atrial conduction and increased heterogeneity of atrial refractoriness that may be responsible for spontaneous initiation and maintenance of the arrhythmia. Reservations about the applicability of observations concerning electrically induced atrial fibrillation to the spontaneous arrhythmia have been made.46 In addition, we did not obtain autocorrelograms during atrial fibrillation; therefore, periods of regularization of RR intervals may have occurred without recognition. However, the structure of RR interval histograms recorded in our experiments were unimodal and skewed to the right as previously reported in spontaneous atrial fibrillation in humans. 14, 32, 34, 36, 38 In addition, the characteristics of atrial fibrillation during continuous stimulation were similar to those of atrial fibrillation that persisted after pacing in those experiments in which the arrhythmia persisted long enough to allow analysis. Furthermore, the changes in RR interval histograms that we observed after the administration of diltiazem were very similar to those reported after oral therapy in humans.14,47
Intravenous diltiazem does not affect intra-atrial conduction time or the HV interval.9 We 
